<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950439</url>
  </required_header>
  <id_info>
    <org_study_id>19-API-02</org_study_id>
    <nct_id>NCT04950439</nct_id>
  </id_info>
  <brief_title>Pyrophosphate and Arterial Calcification in Chronic Kidney Disease</brief_title>
  <acronym>Predical</acronym>
  <official_title>Pyrophosphate: a New Biomarker to Predict Arterial Calcification in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arterial calcifications start at early stages of chronic kidney disease (CKD) and are&#xD;
      associated to cardiovascular mortality. Pyrophosphate (PPi) is an endogenous compound, which&#xD;
      stops the mineralization process in bones and is expected to act at ectopic sites. In uremic&#xD;
      rats, low PPi plasma levels are associated with high calcium content in the aorta and&#xD;
      peritoneal administration of PPi blocks this process. People on maintenance dialysis or&#xD;
      kidney transplant recipients have low plasma levels of PPi and show high scores of arterial&#xD;
      calcification. The purpose is to determine the role of low PPi in the development of arterial&#xD;
      calcifications in patients with CKD stage 3 or 4. To that aim, 252 patients with eGFR between&#xD;
      59 et 20 ml/min/1,73 m2 will be recruited and will be examined at baseline and three years&#xD;
      later.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 6, 2021</start_date>
  <completion_date type="Anticipated">December 6, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 6, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of PPI</measure>
    <time_frame>3 years</time_frame>
    <description>To show that low plasma levels of PPi at baseline is associated with a high progression of arterial calcification at three years after adjustment for confounding variables</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Myocardial CT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The investigator will collect the usual clinical history and data. Risk factors and cardiovascular events are identified. A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collect blood sample</intervention_name>
    <description>A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.</description>
    <arm_group_label>Myocardial CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  eGFR between 59 et 20 ml/min/1,73 m2 twice at three month interval&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. kidney transplantation&#xD;
&#xD;
          2. acute inflammatory disease or active cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Favre Guillaume, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice, Service de NÃ©phrologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Favre Guillaume, PhD</last_name>
    <phone>0492038428</phone>
    <email>favre.g@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <state>Alpes Maritimes</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Favre Guillaume, PhD</last_name>
      <phone>0492038428</phone>
      <email>favre.g@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Favre Guillaume, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

